Nkarta (NASDAQ:NKTX) Posts Earnings Results, Beats Expectations By $0.05 EPS

Nkarta (NASDAQ:NKTXGet Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.57) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.62) by $0.05, reports.

Nkarta Trading Down 31.3 %

Shares of NKTX opened at $8.92 on Friday. The firm’s 50-day moving average is $10.77 and its two-hundred day moving average is $5.70. Nkarta has a twelve month low of $1.28 and a twelve month high of $16.24. The firm has a market capitalization of $437.70 million, a P/E ratio of -3.72 and a beta of 0.73.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on NKTX shares. Raymond James reissued an “outperform” rating and set a $16.00 price target (up from $13.00) on shares of Nkarta in a report on Friday. Mizuho cut their price target on shares of Nkarta from $31.00 to $25.00 and set a “buy” rating for the company in a report on Friday. Needham & Company LLC reissued a “buy” rating and set a $15.00 price target on shares of Nkarta in a report on Friday. Finally, HC Wainwright cut their price target on shares of Nkarta from $22.00 to $20.00 and set a “buy” rating for the company in a report on Friday.

Get Our Latest Report on Nkarta

Insiders Place Their Bets

In other Nkarta news, CEO Paul J. Hastings sold 9,697 shares of the company’s stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $8.74, for a total transaction of $84,751.78. Following the transaction, the chief executive officer now directly owns 390,507 shares in the company, valued at $3,413,031.18. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, CEO Paul J. Hastings sold 9,697 shares of the stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $8.74, for a total value of $84,751.78. Following the sale, the chief executive officer now directly owns 390,507 shares in the company, valued at $3,413,031.18. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider James Trager sold 4,143 shares of the stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $12.00, for a total transaction of $49,716.00. Following the completion of the sale, the insider now owns 149,415 shares in the company, valued at $1,792,980. The disclosure for this sale can be found here. Over the last three months, insiders have sold 17,392 shares of company stock worth $165,512. 5.60% of the stock is owned by company insiders.

Institutional Trading of Nkarta

Large investors have recently modified their holdings of the business. Sei Investments Co. acquired a new stake in shares of Nkarta in the second quarter valued at approximately $27,000. Natixis acquired a new stake in Nkarta during the fourth quarter worth approximately $28,000. Advisor Group Holdings Inc. boosted its position in Nkarta by 13,661.1% during the fourth quarter. Advisor Group Holdings Inc. now owns 4,954 shares of the company’s stock worth $29,000 after acquiring an additional 4,918 shares during the last quarter. Bourgeon Capital Management LLC acquired a new stake in Nkarta during the fourth quarter worth approximately $30,000. Finally, American Century Companies Inc. boosted its position in Nkarta by 59.9% during the third quarter. American Century Companies Inc. now owns 21,817 shares of the company’s stock worth $30,000 after acquiring an additional 8,177 shares during the last quarter. 80.54% of the stock is currently owned by institutional investors and hedge funds.

Nkarta Company Profile

(Get Free Report)

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.

Featured Articles

Earnings History for Nkarta (NASDAQ:NKTX)

Receive News & Ratings for Nkarta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nkarta and related companies with MarketBeat.com's FREE daily email newsletter.